Mankind Pharma Limited — Board/Management Information 2025

Jul 14, 2025

==> picture [559 x 53] intentionally omitted <==

==> picture [559 x 55] intentionally omitted <==

July 14, 2025

BSE Limited

P J Towers, Dalal Street, Mumbai – 400 001

Scrip Code: 543904

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation of Board Meeting under Regulation 29 & 50 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant to Regulation 29 & 50 of the Listing Regulations, we wish to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Thursday, July 31, 2025, inter-alia to consider:

• i. and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30, 2025; and

ii. declaration of interim dividend, if any, for the financial year 2025-26.

Further, in continuation of our earlier letter dated June 26, 2025 under subject ‘Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till August 2, 2025.

The above notice is also being uploaded on the website of the Company at www.mankindpharma.com.

You are requested to take note of the same.

Thanking You,

Yours Faithfully,

For Mankind Pharma Limited

HITESH Digitally signed by HITESH KUMAR KUMAR JAIN Date: 2025.07.14 JAIN 21:49:01 +05'30' Hitesh Kumar Jain Company Secretary and Compliance Officer

==> picture [557 x 60] intentionally omitted <==